05 jan: DSV, 642 - Storaktionærmeddelelse
06 jan: Indre værdi af SmallCap Danmark A/S er opgjort til 84,4 kr. pr. ..
06-01-2017 07:58:46

Knud Vindfeldt steps down from the Executive Board of Chr. Hansen Holding A/S

Relateret indhold
11:38 - 
Aktier/middag: Novo styrker grønt C25 efter positive st..
10:27 - 
Chr. Hansen/UBS: Sænker anbefaling til "neutral" fra "k..
09:19 - 
Aktier/åbning: Novo til tops i positiv start for C25
Relateret debat
09 jun - 
Har stadig mine købt i kurs 115 :-)
09 jun - 
Super Alpe, tak for hjælpen. Jeg holder fast i mine lid..
09 jun - 
Den er uændret stærk i optrend, med obs på at købssigna..

Hoersholm, 2017-01-06 07:58 CET (GLOBE NEWSWIRE) --

 

Company announcement No. 01/2017

After more than 25 years with Chr. Hansen and 11 years in Executive Management, Knud Vindfeldt will step down from the Executive Board of Chr. Hansen Holding A/S on 28 February 2017.

Knud Vindfeldt joined Chr. Hansen in 1991 and was appointed member of the Executive Board of Chr. Hansen Holding A/S and head of the Cultures & Enzymes Division in 2005, and was further appointed COO and Deputy CEO in 2016. After February, Knud will continue to support Chr. Hansen in the role of advisor to the CEO for a period of six months.

Cees de Jong, CEO of Chr. Hansen, says: “Knud has been one of the key drivers behind the success of Chr. Hansen in the dairy market, and he has relentlessly pushed for continued improvements in our strategic, operational and financial performance. The results delivered by the Food Cultures & Enzymes Division (FC&E) speak for themselves; since 2005, both revenue and EBIT margin have more than doubled.

“With the transfer of the commercial responsibility for FC&E to Christoffer Lorenzen in April last year, the recent recruitment of Thomas Schäfer as Chief Scientific Officer and, today, with the promotion of Torsten Steenholt to Executive Vice President, Global Operations and member of the Corporate Leadership Team, we have ensured Knud’s succession. On behalf of the entire Chr. Hansen organization, I would like to thank Knud for his exceptional contribution to Chr. Hansen and wish him all the best for the future.”

Knud Vindfeldt says: “Chr. Hansen is a truly great company and it has been a fantastic journey, which I am proud to have been part of. The company is in better shape than ever, delivering solid results. With such strong successors in place, I feel confident that this is a natural time for me to step down. In the coming months, we will ensure a good handover.”

Following this change, the Executive Board will consist of CEO Cees de Jong and CFO Søren Westh Lonning. In addition, and as previously announced, Thomas Schäfer will join Chr. Hansen as CSO and member of the Executive Board in due course.

For further information, please contact:

Anders Mohr Christensen, Senior Director, Investor Relations

Tel.: +45 4574 7618

Camilla Lercke, Head of Media Relations

Tel.: +45 5339 2384

 

About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2015/16 financial year was EUR 949 million. The company has more than 2,700 dedicated employees in 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen A/S. For further information, please visit www.chr-hansen.com.

 

Vedhæftet fil: No 01 2017 US.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Novo Nordisk/CSO: Vi står i en unik situation

21-06-2018 13:46:41
Novo Nordisk står i en unik position med diabetespillen oral Semaglutid, som i nye studieresultater giver nogle af verdens bedst sælgende diabetesmidler baghjul.Resultaterne fra de pågældende fase 3-studier overstiger forventningerne hos Novo Nordisks forskningsdirektør, Mads Krogsgaard Thomsen, som ser produktet blive verdens bedste tabletbaserede præparat - og dermed også det bedst sælgende. - D..

Ambu/Nordea: Indleder dækningen med "sælg" - 2020-målet for højt - NY

21-06-2018 09:48:10
Nordea indleder dækningen af Ambu-aktien med anbefalingen "sælg". Banken vurderer blandt andet, at Ambus 2020 mål om et salg på 5 mia. kr. er for højt, og at mængden af tidligere opjusteringer har sendt forventningerne op til uholdbare niveauer.Det skriver banken i en analyse.Ambus indtræden i gastrointestinal (GI) endoskopi, hvor Ambu udvikler udstyr til eksempelvis at kunne lave en kikkertunders..

Aktier/tendens: Novo og Chr. Hansen i fokus fra start

21-06-2018 08:19:54
Stærke tendenser for de amerikanske aktier ventes torsdag at sende positive vibrationer ind over aktiemarkederne i Europa, hvor en "dark horse" dog er markedets reaktion på den nedjustering, som den tyske bilgigant Daimler kom med onsdag aften. - Det ser ud til, at vi får lov til at starte lidt bedre op, end man ellers kan frygte, når der er så meget usikkerhed derude. En af de ting, som bliver sp..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Novo og Chr. Hansen i fokus fra start
2
Novo/Sydbank: Flotte data kan sikre høj pris til ny diabetespille - NY
3
Onsdagens aktier: Rekord-Ambu satte C25 til vægs
4
Novo/Jefferies: Spår stadig milliardsalg af oral Semaglutid
5
Vestas/Jyske: Potentiale for rekord i kvartalet og god udsigt til 2019

Relaterede aktiekurser

Chr Hansen Holding A/S 625,60 -2,0% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. juni 2018 16:10:02
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180619.1 - EUROWEB3 - 2018-06-21 16:10:02 - 2018-06-21 16:10:02 - 1 - Website: OKAY